that influence HCV disease progression including steatosis, obesity, insulin
resistance, diabetes, race/ethnicity, and general studies on disease
62. Risk of Hepato-Pancreatico-Biliary Tumors Following Hepatitis C Virus
Infection: a Population-based Study on U.S. Veterans
Envelope Protein of the Hepatitis C virus (E2) inhibits IL-2 Secretion from T
non-parenchymal liver cells are potent suppressors of HCV replication.
o 438a. A comparison of risk
factors for intra- and extrahepatic cholangiocarcinoma in the United States: a
population-based case-control study.
o M1779. Hyperlipidemia is very
infrequent but is undertreated in chronic HCV. (updated,
o M1783. Statins Improve ALT values
in Chronic Hepatitis C Patients with Abnormal Values. (updated, May 21)
o M1788. Liver disease in hepatitis
C virus carriers found at the occasion of blood donation and outcomes with or
without interferon treatment: A study on 1019 carriers followed for 5-10 years.
o M1810. Serum Leptin
Concentrations In Chronic Viral Hepatitis: A Clinical Approach.
o M1820. Regulatory failure of
serum prohepcidin levels in patients with hepatitis C
o M1826. Hepatitis C and End Stage
Renal Disease: A Global Survey.
o M1829. Proteinuria in chronic
HCV infection: a link for chronic kidney disease (CKD)?
o M1836. Prevalence of Gallstones
Among Persons With Hepatitis C Virus Infection In Pakistan (updated,
o M1837. Co-infection with
Cytomegalovirus in Chronic Hepatitis C Infection
o M.1839 Early Occult Portal
Hypertension in Chronic Hepatitis C (updated, May 28)
o S1055 Comorbid Medical and Psychiatric Illness and
Substance Abuse in HCV-Infected and Uninfected Veterans (updated, May 20)
hepatocyte growth factor activator inhibitor type 1 is positively associated
with hepatic fibrosis in patients with chronic hepatitis C virus infection.
o M1838. Clinical Spectrum of
Chronic Hepatitis C Virus-related Cryoglobulinemia in the US. (updated, May 21)
o M1843. Associations among Susceptibility Factors for Human
Porphyria Cutanea Tarda (updated, May 21)
M1853. Outcomes of pegylated interferon
and ribavirin therapy for HCV patients with cryoglobulinemia as compared to
patients without cryoglobulinemia.. (updated, May 21)
o 513. Associate Factors Of
Nonalcoholic Fatty Liver Disease : Results From A Population-Based Study
association of selected adipokines with hepatic steatosis in patients with
chronic hepatitis C infection.
M1822. The association of
adipokine levels with changes in steatosis following treatment in patients with
chronic hepatitis C infection.
M1823. Chronic HCV Infection
causes Insulin Resistance- A Meta-analysis. (updated, May 23)
o M1831. Metabolic predictors of
steatosis and fibrosis in chronic hepatitis C(HCV). (updated,
M1832. Lack of association
between hepatitis C and diabetes mellitus: a case-control study. (updated, May 23)
o S2158. Prevalence and associated factors
of nonalcoholic liver fatty disease and metabolic syndrome: results from a
o T1064. Health Utility Assessment
Using SF-6D and Health Utility Index (HUI) in Patients with Chronic Viral
Hepatitis and Non-alcoholic Fatty Liver Disaese (NAFLD).
o T1072. Outcome of Japanese patients with cirrhosis due to
nonalcoholic steatohepatitis(NASH) and hepatitis C. (updated, May
o M1792. Clinical cirrhosis in
chronic hepatitis c (CHC) varies by race-ethnicity. (updated, May 22)